EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial

David E Kandzari iD, Felix Mahfoud iD, Raymond R Townsend iD, Kazuomi Kario iD, Michael A Weber iD, Roland E Schmieder iD, Konstantinos Tsioufis iD, Stuart Pocock iD, Minglei Liu, Vanessa DeBruin, Sandeep Brar iD, Michael Böhm iD

Circulation: Cardiovascular Interventions · 2025-07 · 18 (7)

DOI: 10.1161/circinterventions.125.015194 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2025-07. Verfasst von David E Kandzari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Piedmont Heart Institute, Atlanta, GA (D.E.K.). Hauptthemen laut MEDLINE: Blood Pressure, Hypertension, Kidney, Renal Artery. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Six-month results from the SPYRAL HTN-ON MED trial (SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral Multi-Electrode Renal Denervation System) demonstrated that renal denervation (RDN) reduced office blood pressure (BP), and not 24-hour ambulatory systolic BP, compared with sham control in hypertensive patients. In this prespecified analysis of the ON MED trial, long-term changes in BP, antihypertensive drug use, and safety outcomes through 24 months are compared between RDN and sham control groups. METHODS: SPYRAL HTN-ON MED is a prospective, randomized, sham-controlled, blinded trial enrolling 337 patients globally from 56 clinical centers. Eligible patients had an office systolic BP of 150 to 180 mm Hg, a diastolic BP ≥90 mm Hg, and a 24-hour ambulatory systolic BP of 140 to 170 mm Hg. Patients were randomized to RDN or a sham control procedure and were prescribed a stable regimen of 1 to 3 antihypertensive medications through 6 months. After 6 months, patients and physicians were unblinded with permitted changes to antihypertensive therapy, and control patients were permitted to cross over. Crossover patients had their last observations carried forward as part of the control group. Statistical analyses were conducted on the population as randomized. RESULTS: At 24 months, the RDN group experienced significantly greater mean reductions in ambulatory systolic BP (−12.1±15.3 mm Hg [n=176] versus −7.0±13.1 mm Hg [n=33]; difference: −5.7 mm Hg; P =0.039) and office systolic BP (−17.4±16.1 mm Hg [n=187] versus −9.0±19.4 mm Hg [n=35]; difference: −8.7 mm Hg; P =0.0034) compared with sham controls. At 24 months, antihypertensive medications increased significantly more in the sham group (1.7 versus 2.7) compared with the RDN group (1.8 versus 2.4; P =0.046). Sensitivity analyses accounting for missing sham patient BP values due to crossover yielded consistent results in favor of RDN for 24-hour ambulatory ( P =0.023) and office systolic BP ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PressureHypertensionKidneyRenal ArterySympathectomyAgedFemaleHumansMaleMiddle AgedAntihypertensive AgentsBlood Pressure Monitoring, AmbulatoryProspective StudiesTime FactorsTreatment Outcome

Stichwörter der Autor:innen

antihypertensive agentsblood pressuredenervationhypertension

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Piedmont Heart Institute, Atlanta, GA (D.E.K.).
  • Department of Cardiology (F.M.), University Heart Center, University Hospital Basel, Switzerland.
  • Cardiovascular Research Institute Basel (CRIB) (F.M.), University Heart Center, University Hospital Basel, Switzerland.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia (R.R.T.).
  • Department of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan (K.K.).
  • SUNY Downstate College of Medicine, New York, NY (M.A.W.).

ORCID-Profile: David E Kandzari, Felix Mahfoud, Raymond R Townsend, Kazuomi Kario, Michael A Weber, Roland E Schmieder, Konstantinos Tsioufis, Stuart Pocock, Sandeep Brar, Michael Böhm

Zitieren

APA

Kandzari, D. E., Mahfoud, F., Townsend, R. R., Kario, K., Weber, M. A., Schmieder, R. E., Tsioufis, K., Pocock, S., Liu, M., DeBruin, V., Brar, S., & Böhm, M. (2025). Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial. Circulation: Cardiovascular Interventions, 18(7). https://doi.org/10.1161/circinterventions.125.015194

Vancouver

Kandzari DE, Mahfoud F, Townsend RR, Kario K, Weber MA, Schmieder RE, et al. Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial. Circulation: Cardiovascular Interventions. 2025;18(7). doi:10.1161/circinterventions.125.015194

BibTeX
@article{Kandzari2025,
  author = {Kandzari, David E and Mahfoud, Felix and Townsend, Raymond R and Kario, Kazuomi and Weber, Michael A and Schmieder, Roland E and Tsioufis, Konstantinos and Pocock, Stuart and Liu, Minglei and DeBruin, Vanessa and Brar, Sandeep and Böhm, Michael},
  title = {Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {7},
  doi = {10.1161/circinterventions.125.015194}
}
Kostenlos starten →